Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis

Free AI-powered analysis and research for Vanda Pharmaceuticals Inc. stock

Sector: Healthcare

Analyze Vanda Pharmaceuticals Inc. (VNDA) Stock

Vanda Pharmaceuticals Inc. (VNDA) is a leading company in the Healthcare sector. Use StockIQ's free analysis tool to get comprehensive insights into VNDA stock performance, technical indicators, and AI-powered trading recommendations.

Get instant AI-powered analysis including technical indicators, fundamental analysis, risk assessment, and trading insights for Vanda Pharmaceuticals Inc. stock.

Analyze VNDA Now →

📰 Latest Update

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Mon, August 24, 2026 at 11:00 AM UTC 4 min read

Vanda Pharmaceuticals has received Orphan Drug Designation from the European Commission for its investigational drug Imsidolimab, aimed at treating Generalized Pustular Psoriasis. This designation is significant as it may provide Vanda with various incentives, including market exclusivity and potential financial benefits, which could enhance the company's growth prospects. Investors may view this development positively, as it highlights Vanda's commitment to addressing unmet medical needs in dermatology.

Read full article →